COMMUNIQUÉ DE PRESSE
News
-
-
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Formycon announces decision on Phase III trial with FYB206 and provides update on potential need to adjust the valuation of FYB202 and FYB201
Formycon terminates Phase III trial for FYB206 after FDA feedback, anticipates valuation adjustments for FYB202 & FYB201 due to price discounts -
-
-
COMMUNIQUÉ DE PRESSE
Lotus Pharmaceutical becomes strategic partner for the commercialization of Formycon’s Eylea® biosimilar FYB203/AHZANTIVE® in the Asia-Pacific Region
Formycon AG announces strategic partnership with Lotus Pharmaceutical for commercialization of Eylea biosimilar FYB203/AHZANTIVE in Asia-Pacific region -
-
-
COMMUNIQUÉ DE PRESSE
Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama®
Formycon receives EU approval for biosimilar FYB203 (aflibercept) to Eylea®, brands AHZANTIVE® and Baiama® for nAMD and retinal diseases. Teva to market AHZANTIVE® in Europe
